share_log

Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target

Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target

富國銀行將Sangamo Therapeutics的評級下調至同等權重,宣佈1美元的目標股價
Benzinga ·  2023/11/06 08:21

Wells Fargo analyst Jim Birchenough downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and announces $1 price target.

富國銀行分析師吉姆·伯奇諾將Sangamo Therapeutics(納斯達克股票代碼:SGMO)的評級從增持下調至同等權重,並宣佈了1美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論